Lexaria Bioscience (LEXX) Cash & Equivalents (2010 - 2026)

Lexaria Bioscience has reported Cash & Equivalents for 17 years, with the latest figure at $3.5 million in Q2 2026.

• Quarterly Cash & Equivalents fell 24.32% year-over-year to $3.5 million in Q2 2026, while the trailing twelve-month figure through May 2026 was $3.5 million (down 24.32% YoY) and the FY2025 annual result came in at $1.8 million, down 72.27% from the prior year.
• Cash & Equivalents eased to $3.5 million in Q2 2026 per LEXX's latest filing, from $5.1 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $8.5 million in Q2 2024 and troughed at $1.4 million in Q3 2023.
• A 5-year average of $4.9 million and a median of $4.6 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents tumbled 76.74% in 2023, then soared 380.72% in 2024.
• Over 5 years, Cash & Equivalents stood at $4.5 million in 2022, then plunged by 56.89% to $2.0 million in 2023, then jumped by 313.39% to $8.1 million in 2024, then sank by 47.0% to $4.3 million in 2025, then dropped by 18.83% to $3.5 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $3.5 million, $5.1 million, and $4.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.